Kornimate/medical-research-clean huggingface dataset:
a multi-center, retrospective analysis of clinical character, outcome and prognosis of lymphoepithelioma-like carcinoma

Conditions: Lymphoepithelioma-Like Carcinoma; Lymphoepithelioma-Like Carcinoma of Thymus; Lung Cancer

Summary: the investigators retrospective collect the clinical data of patients diagnosed with lymphoepithelioma-like carcinoma, including primary site, gender, age, smoking history, tumor stage, time of initial treatment, ebv-dna copy number, first-line treatment and survival status.

lymphoepithelioma-like carcinoma (lelc) is a rare ebv-related tumor. its histology is similar to that of nasopharyngeal carcinoma. in 2004, the who classified lelc into one subtype of large cell carcinoma, and the 2015 who classified it as other and unclassified cancers. lelc can originate in many organs, including parotid glands, throat, lungs, digestive tract, genitourinary system, etc. driver gene mutations are rarely seen, and most of them are pd-l1 positive. in terms of treatment, there is no standard first-line treatment for lymphoepithelioma-like cancer. patients with early-stage lymphoepithelioma-like cancer can receive surgery or radiotherapy, while palliative radiotherapy or chemotherapy is the main treatment for patients in advanced stage. the survival time is about 107 months, the 5-year os is 59.5%, which is better than the prognosis of lung squamous cell carcinoma in the same period. a retrospective study of sun yat-sen university cancer hospital included 127 patients with advanced lung lelc who received first-line chemotherapy between 2007 and 2018. gemcitabine and platinum based chemotherapy and paclitaxel and platinum based regimens are significantly better than pemetrexed and platinum, but most of the current studies on lymphoepithelioma-like cancer focus on lelc that originates in the lung. but for other sites, such as parotid glands, liver, digestive tract, are mostly based on case reports, and there are few retrospective studies with large samples to explore their clinical features and treatment outcome. therefore, investigators designed this retrospective clinical study to analyze the clinical characteristics, treatment, survival, and prognostic risk factors of patients with lymphoepithelioma-like carcinoma in order to summary the clinical character and guide treatment.

Eligibility criteria:
inclusion criteria: * 1. lymphoepithelioma-like carcinoma confirmed by histopathology; * 2. the primary lesion does not involve the nasopharynx; * 3. complete data for patient's character, laboratory and imaging test, treatment and follow-up are available. exclusion criteria: * 1. concomitant with other tumor components at the time of diagnosis; * 2. have a history of any other malignant tumors; * 3. lack of complete data
a study of 4-1bb agonist pf-05082566 plus pd-1 inhibitor mk-3475 in patients with solid tumors (b1641003/keynote-0036)

Conditions: Advanced Solid Tumors

Summary: this is a safety, pharmacokinetic and pharmacodynamic study designed to estimate the maximum tolerated dose (mtd), and determine the recommended phase 2 dose (rp2d) of pf-05082566, a 4-1bb agonist monoclonal antibody (mab), in combination with mk-3475, a pd-1 inhibitor in patients with solid tumors.


Eligibility criteria:
inclusion criteria: * histological or cytological diagnosis of advanced/metastatic solid tumor malignancy which has progressed on standard therapy or for which no standard therapy is available. * measurable disease per recist v1.1. * adequate bone marrow, renal and liver functioning exclusion criteria: * cns primary malignancies, active seizure disorder or spinal cord compression, or carcinomatous meningitis. * history of any of the following toxicities associated with a prior immunotherapy: * grade 3 immune mediated adverse event that was considered related to previous immunotherapy and required immune suppressive therapy; * grade 2 hepatic function related adverse event that persisted more than 1 week, was considered related to immunotherapy, or required treatment discontinuation or immunosuppressive therapy * any of the following within the 12 months prior to registration: myocardial infarction, uncontrolled angina, coronary/peripheral artery bypass graft, symptomatic congestive heart failure, cerebrovascular accident or transient ischemic attack and 6 months for deep vein thrombosis or pulmonary embolism. * history of or known presence of extensive, disseminated/bilateral or grade 3 or 4 interstitial fibrosis or interstitial lung disease, including a history of pneumonitis, hypersensitivity pneumonitis, interstitial pneumonia, interstitial lung disease, obliterative bronchiolitis, or pulmonary fibrosis, but not including a history of prior radiation pneumonitis. patients with clinically significant lung disease requiring oxygen therapy (eg, copd).

Keywords: advanced solid tumors
mucosal innate immune activation in chronic intestinal disorders

Conditions: Irritable Bowel Syndrome; Inflammatory Bowel Diseases

Summary: crohn's disease and ulcerative colitis are types of chronic intestinal disorder called inflammatory bowel diseases (ibd) that can affect the small and large bowel causing symptoms of abdominal pain, diarrhea, blood in the stool, and weight loss. irritable bowel syndrome (ibs) is a milder form of ibd, with symptoms of abdominal pain, bloating, diarrhea or constipation, and blood in the stool. it is not known what causes diseases such as ibd and ibs. this study will look at the events in the gut that leads to leaky gut and inflammation in patients with ibd and ibs. the study will also see if medications such as rifaximin and mesalamine may reduce the amount of leaky gut.


Eligibility criteria:
inclusion criteria: * men and women, 18-years old and older * presenting at the university of arkansas for medical sciences (uams) endoscopy center to undergo endoscopy with biopsy for surveillance, screening or diagnosis. exclusion criteria: * subjects classified in an anesthesia risk group , american society of anesthesiologists class (asa) ≥ 4, * history of bleeding diathesis or coagulopathy * stroke or transient neurological attack within the last 6 months * pregnancy * currently on blood thinners (excepting aspirin) * subject is unable to consent themselves
safety and efficacy of cladribine therapy after anti cd20 therapy

Conditions: Multiple Sclerosis

Summary: prolonged anti cd20 therapy for the treatment of active multiple sclerosis leading to continuous b cell depletion is associated with hypogammaglobulinemia predisposing to a potentially increased risk of serious infections, particularly in the more disabled and aged patients. no data have been published on the sequential use of anti cd20 therapies and cladribine, that is thought to act as an immune reconstitution agent. his study aims at investigating igg and igm serum concentration changes at 6 and 12 months after switching to cladribine in patients previously treated with anti cd20 therapies (ie, ocrelizumab ≥1.8 gr or rituximab 3.0 gr) for ≥18 months, as compared to continued anti cd20 therapies.

the study population will include patients with remitting relapsing multiple sclerosis consulting the multiple sclerosis center of neurocenter of southern switzerland. enrolled patients will have 5 study visits, one every 3 months according to clinical practice. at visits at 3 and 6 months only adverse events will be collected for study purposes. clinical assessments will be performed at baseline, month 6 and month 12. clinical assessments correspond to medical exams performed routinely in ms patients treated with anti cd20 or cladribine therapy: clinical assessments, monitoring haemoglobin parameters, serum immunoglobulins, liver and renal function.(6, 12 months), radiological disability progression and biomarker of ongoing neurodegeneration (12 months).

Eligibility criteria:
inclusion criteria: * relapsing ms according to lublin; * treatment with ocrelizumab or rituximab for ≥18 months and having received 1.8 / 3.0 gr, respectively; * clad_group: planning to switch to cladribine because of concerns about increased risks of infections related to hypogammaglobulinemia developing during long term anti cd20 therapies or a documented decrease of ≥10% igg and/or igm compared to pre- anti cd20 therapy; * or cd20_group: no need to stop cd20 therapy due decrease of ≥10% igg and/or igm, or increased risk of infections related to hypogammaglobulinemia or other reasons, continued anti cd20 therapies clinically indicated; * edss ≤7.0; * age \>18 years. exclusion criteria: * non relapsing ms; * pregnancy - breastfeeding; * contraindications to perform mri; * contraindication to receive cladribine or to continue anti cd therapies

Keywords: anti cd20 therapy cladribine
the effect of time restricted eating on glycemic and proinflammatory biomarkers among prediabetic obese jordanian adults aged 18-40 years old

Conditions: Insulin Resistance; Inflammation Biomarkers; Time Restricted Eating; Caloric Restriction; Obesity (Disorder)

Summary: obesity, a global epidemic, significantly contributes to prediabetes, cardiovascular diseases, and other chronic diseases due to its pro-inflammatory nature. this studyl investigates the effects of time-restricted eating (tre) with calorie restriction (cr), tre without cr, and cr without tre on glycemic control and pro-inflammatory biomarkers among prediabetic obese jordanian adults aged 18-40 years. the study assesses changes in pro-inflammatory biomarkers (il-1β, tnf-α, il-6), insulin resistance (homa-ir), and body composition over 12 weeks. participants (n=120) will be randomized into four intervention arms: (1) tre with cr, (2) tre without cr, (3) cr without tre, and (4) a control group with no dietary restrictions and no tre. biweekly anthropometric assessments will evaluate pro-inflammatory biomarkers and biochemical measures at baseline and the end of the study. the findings will provide insights into the comparative effectiveness of tre and cr, potentially offering a safe, cost-effective intervention to prevent obesity-induced inflammation, prediabetes, and progression to type 2 diabetes mellitus.


Eligibility criteria:
inclusion criteria: * ir individuals diagnosed with ir by the physicians as indicated by homa-ir score * female and male, bmi ≥ 30 to 39.9 kg/m2 * age between 18 and 40 years * stable weight for 3 months before the beginning of the study * sedentary lifestyle exclusion criteria: * previous weight loss surgery * pregnancy or intent to become pregnant * breastfeeding * chronic diseases * drug therapies that could interfere with the effectiveness of the dietary intervention (e.g., use of corticosteroids, and anti-diabetic drugs) * diabetic type 1 and 2 individuals * anyone physically active to reduce the influence of confounding covariates

Keywords: time restricted eating insulin resistance obesity caloric restriction inflammation cytokines
extracorporeal therapy for the removal of myoglobin using the cytosorb in patients with rhabdomyolysis

Conditions: Rhabdomyolysis

Summary: prospective, randomized non-blinded, controlled study to assess the feasibility of the cytosorb as an adjunct to the standard of care in patients with rhabdomyolysis requiring renal replacement therapy.


Eligibility criteria:
inclusion criteria: * subject is age 18-80 * subjects present with rhabdomyolysis * subject requires renal replacement therapy and has undergone adequate volume resuscitation * subject is willing to comply with specified follow up requirements exclusion criteria: * subject or their legal guardian either declines or cannot give informed consent * subject is pregnant * subject has been previously enrolled in this clinical study * comorbid condition that may limit survival to ≤14 days * comorbid condition that could confound study results * subjects who are receiving immunosuppressive therapy
short term outcome following post operative enhanced recovery implementation in patients with perforated peptic ulcer

Conditions: Emergent Surgery; Perforated Peptic Ulcer

Summary: this study aimed to evaluate the effect of implementing post operative enhanced recovery on perforated peptic ulcer surgery outcome. the current study anticipated better outcomes in the form of early functional recovery, reduced length of hospital stays, less thirty days post operative morbidity, and better gastrointestinal quality of life after implementing post operative enhanced recovery in patients with perforated peptic ulcer.

this study aimed to evaluate the effect of implementing post operative enhanced recovery on perforated peptic ulcer surgery outcomes. methods: quasi- experimental research design was utilized. the study was conducted at assiut university hospital. a purposive sample of thirty patients (study group) who received postoperative enhanced recovery after open surgical repair of perforated peptic ulcer compared with thirty patients (control group) who exposed to routine care. patient assessment sheet and gastrointestinal quality of life index were the tools used for data collection.

Eligibility criteria:
inclusion criteria: * age ranged from 18 to 65 years, * diagnosed with perforated peptic ulcer, * ulcer size less than 10 mm. * underwent emergent surgical intervention exclusion criteria: * malignant ulcer. * other git diseases (corn's disease \& ulcerative colitis) * pregnant women * psychiatric or neurological illness. * who refused to participate in the study
tamoxifen pharmacogenetics in asian breast cancer women

Conditions: Poisoning by, Adverse Effect of and Underdosing of Tamoxifen

Summary: the clinical outcome of tamoxifen treatment in breast cancer patients may be influenced by the activity of cytochrome p450 enzymes involving in tamoxifen biotransformation.

the investigators investigated the prognostic and/or predictive value of genetic polymorphisms of enzymes involved in tamoxifen metabolism for the treatment outcome among asian breast cancer patients.

Eligibility criteria:
inclusion criteria: * incident breast cancer patients who underwent surgery exclusion criteria: * previous cancer history before breast cancer diagnosis

Keywords: tamoxifen pharmacogenomics breast cancer
levothyroxine replacement with liquid gel capsules vs tablets post-thyroidectomy

Conditions: Thyroid Cancer; Postsurgical Hypothyroidism

Summary: in some patients, levothyroxine liquid gel capsules may demonstrate superior absorption than the tablet option. impaired absorption of thyroid hormone directly correlates to higher and more unpredictable tsh (thyroid stimulating hormone) levels. the investigators therefore hypothesize that following thyroidectomy for stage i/ii differentiated thyroid cancer the gel capsule levothyroxine formulation will provide more predictable tsh results and in turn require fewer dose adjustments to achieve optimal hormone levels in the postoperative period. the aim of this investigation is to compare the use of levothyroxine in liquid gel capsules to tablet form for tsh suppression following thyroidectomy for presumed stage i/ii differentiated thyroid cancer.

ten patients will be randomized prior to surgery to receive levothyroxine in tablet form and ten patients will be randomized to receive in gel capsule form. both forms will be encapsulated in order to allow double-blinding of the study. the postoperative goal tsh will be between 0.1 and 0.5 mu/l (milli units per litre) in both arms. patients will be seen at weeks 6, 12 and 18 postoperatively and have tsh and free t4 measured. the primary outcome is the number of patients at each visit that are at goal range tsh. a secondary analysis will compare the dose changes required between the two groups in order to achieve goal tsh. another secondary analysis will investigate the patients' quality of life. two different surveys (see secondary outcomes below) will be performed at both study entry and completion to compare the two groups.

Eligibility criteria:
inclusion criteria: * age \> 18 years * presumed ajcc (american joint committee on cancer) tumor stage i or ii * planned total or near-total thyroidectomy * planned goal tsh suppression 0.1-0.5 mu/l for at least 18 weeks postoperatively * normal serum tsh within 12 months preceding surgery exclusion criteria: * ajcc stage iii or greater * undifferentiated, anaplastic or medullary thyroid cancer * planned postoperative tsh goal other than 0.1-0.5 mu/l * history of gastrointestinal malabsorption or gastric bypass surgery * pregnancy * use of medications that alter the absorption or metabolism of levothyroxine * prior use of levothyroxine

Keywords: levothyroxine
study on incidence of elective surgery postponed during covid-19 pandemic in geriatric population

Conditions: Age Problem; Surgery; Depression, Anxiety

Summary: the covid-19 pandemic has disrupted routine hospital services globally. the hospital services include surgeries for benign diseases, cancer surgery and obstetric surgery. a study conducted by covidsurg collaborative estimated that 28,404,603 operations would be cancelled or postponed during the peak 12 weeks of disruption due to covid-19. globally, 81.7% of benign surgery, 37.7% of cancer surgery and 25.4% of elective caesarean sections would be cancelled or postponed. if countries increase their normal surgical volume by 20% post-pandemic, it would take a median 45 weeks to clear the backlog of operations resulting from covid-19 disruption. this study aims to estimate total number of elective operations postponed during covid-19 in geriatric population.

an audit study will be conducted among geriatric patients that are admitted for elective surgeries in university malaya medical center (ummc). patients who fulfil inclusion/ exclusion criteria will be recruited with consent and will have a face-to-face interview in the surgical ward prior to their elective surgeries. data collection in the form of a questionnaire designed in english and filled up by the research interviewer is created to document patient demography, surgical details and level of depression/ anxiety prior to surgery. the primary objective of this study is to find incidence of elective surgeries has postponed during covid-19 pandemic in geriatric population. this overarching aim raises two secondary objectives of the research: 1. to find the incidents of cancer surgeries postponed during covid-19 pandemic in geriatric population. 2. to find the physical and psychological impact of postponed elective surgery in geriatric population during covid-19 pandemic. random convenience sampling will be conducted. data will be collected using redcap (research electronic data capture) system and analyzed using spss software. results will be presented as mean ± standard deviation, median or frequency (percentages) as appropriate. mann-whitney u test will be used for non-normally distributed data while t test will be used for normally distributed data. the qualitative data analysis will be performed using chi-square test or fisher's exact test if insufficient numbers are present. a p value \< 0.05 will be considered statistically significant.

Eligibility criteria:
inclusion criteria: * geriatric patients (aged 65 and above) * all elective surgeries under general anesthesia, regional anesthesia and ala exclusion criteria: * refuse to participate in the study * patients with cognitive disorders such as dementia and alzheimer's disease

Keywords: geriatric population covid-19 pandemic elective surgery
developing restful environments and management strategies for pediatric stem cell transplant patients

Conditions: Stem Cell Transplant Complications; Sleep Disturbance

Summary: pediatric patients undergoing stem cell transplant (sct) are hospitalized for extended periods and are at high risk for sleep disturbances. in order to begin to address the environmental issues that sct recipients face during inpatient hospitalizations, investigators will conduct a single arm pilot study of a program entitled 'developing restful environments and management strategies' (dreams). the program will provide children receiving sct and families with information and a kit that includes tools which may support sleep and circadian health during an inpatient hospitalization.

in prior work, investigators conducted a study in which sound and light levels were recorded at one-minute intervals within an inpatient room on the sct unit at boston children's hospital using noise and light meters. results showed that pediatric sct recipients were consistently exposed to disruptive noise and light. nighttime noise levels always exceeded world health organization recommendations for sleep, with recipients regularly exposed to multiple noise spikes associated with night wakings. while light levels were frequently dim enough to be conducive to sleep at night, participants were rarely exposed to light bright enough to preserve a healthy circadian rhythm during the day, which has the potential to dysregulate sleep at night. as a child's circadian rhythms may be affected by evening light to a greater extent than adults, such light spikes may be particularly disruptive to circadian rhythms in pediatric participants. the relatively low and afternoon-skewed daytime light, combined with the brighter than recommended light during the evening and early night, has been associated with longer hospitalizations and higher morbidity among adults. this is a single-arm pilot study to evaluate the acceptability and feasibility of the dreams intervention program in stem cell transplant pediatric participants to help support families during this critical phase in a participant's sct recovery. the data collected from this study will help understand the practicality of delivering the program to a greater number of participants and conducting clinical research about the program in the setting in which it will be implemented. the research study procedures include screening for eligibility and surveys. participation in this research study is expected to last for about 2 weeks. it is expected that about 10 children will take part in this research study. the american cancer society is supporting this research study with grant funding.

Eligibility criteria:
inclusion criteria: * patient aged 9-17 years. * patient scheduled to receive a stem cell transplant at boston children's hospital. * english speaking child and primary caregiver (parent/guardian). exclusion criteria: -primary team declines permission to approach.